Business, energy, technology, markets and global industry news from Business News Today

Keytruda

PharmaDeviceNews Keytruda
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Representative image of biotech research technology for chronic myeloid leukemia drug development, highlighting how Merck & Co.’s Terns Pharmaceuticals acquisition could sharpen the race for next-generation targeted oncology therapies.
Features & Analysis

Why Merck’s Terns acquisition puts chronic myeloid leukemia back in the oncology dealmaking spotlight

Merck needs more than Keytruda. TERN-701 could make chronic myeloid leukemia a sharper test of its next oncology strategy.

Read More
Pharma & Biotech

Can Immutep Limited convert orphan designation into a credible late-stage oncology program?

FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.

Read More
KEYTRUDA and WELIREG deliver Phase 3 LITESPARK-022 win in adjuvant clear cell renal cell carcinoma, reshaping post-nephrectomy care
Pharma & Biotech

Merck’s KEYTRUDA plus WELIREG cuts recurrence risk in Phase 3 LITESPARK-022 trial for adjuvant clear cell renal cell carcinoma

KEYTRUDA plus belzutifan cuts recurrence risk in adjuvant RCC. Explore what LITESPARK-022 changes for kidney cancer treatment.

Read More
Representative image of a melanoma lesion under examination. Moderna and Merck’s 5-year data show their personalized mRNA cancer vaccine may significantly reduce recurrence in high-risk cases.
Pharma & Biotech

Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma

Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or

Read More
A representative image of bladder cancer treatment. As PADCEV and Keytruda show promise in transforming perioperative care, new platinum-free regimens are reshaping how muscle-invasive bladder cancer is managed.
Pharma & Biotech

PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients

Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival

Read More